预约演示

With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio

2024-06-20

临床1期

Syncona owns a 23% stake in Netherlands-based iOnctura.

Syncona has added two up-and-coming cancer comiOncturao its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.

Synconadon-based investment firm ledcancer0 million euros ($85.7 million) series B financing for iOnctura, who also included backers like EIC Fund, the venture arm of the European Innovation Council, M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund. Syncona has personally put 30 million euros ($32.1 million) into the company, resulting in a 23% stake in iOnctura.

The Netherlands-based biotech is focused on lead asset roginolisib, which is described as the firiOncturateric modulator of PI3Kδ. The canEIC Fundas already demonstrated lEuropean Innovation CouncilngM VenturesinInkef Capitalrial in a rare eye cancer called uvea3B Future Health FundbiSynconaaid in a June 20 release.iOnctura

iOnctura plans to use the newly gained cash to push rogroginolisibrther into the clinic. This will include launching trials PI3Kδe drug in other indications this year, including non-small cell lung cancer and primary myelofibrosis.rare eye cancer uveal melanoma (UM)

iOnctura, no company has been able to successfully troginolisibwell-known cancer pathway with sufficient precision,” Roel Bulthuis, managing partner and head of investments at Synon-small cell lung canceremberprimary myelofibrosis the release. “By allosterically modulating PI3Kδ, iOnctura has achieved a new level of precision and could be the first company to develop a clinically meaningful medicine targeting this pathway.”

The biotech has a second clinical-stage asset in the form of an autotaxin cancertor called cambritaxestat. The drug is currently in a phase 1b study to treat metastatic pancreaSynconacer in combination with chemotiOnctura PI3Kδ iOnctura

The other cancer-focused biotech that Syncona has parked in its autotaxin inhibitor autotaxin is Yellowstone, acambritaxestatmpany targeting human leukocyte antigen (HLA) class Imetastatic pancreatic cancerommon cancers.

Syncona hacancern the preclinical compSynconaich spun out of the University oYellowstone16.5 million ($20.9 million) in series A funds to build up its pipeline. The biotech is founded on the wcancersParesh Vyas, Ph.D., a professor of hematology at the university who built up a biobank of samples from over 3,000 patients with acute myeloid leukemia (AML).

Synconal of Yellowstone is to develop soluble bispecific TCR-baseUniversity of Oxfordting HLA class II presented peptides on the surface of cancer cells. The company will initially focus its lead program in AML, but also has its eyes on ovarian cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, breast canacute myeloid leukemia (AML)ma.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构